|  |  |
| --- | --- |
|  |  |
|  |

**Fast-track resubmission proforma**

This proforma should be completed for resubmissions where the **only** change to the original submission is a new or improved simple Patient Access Scheme (PAS) or confirmed list price reduction. For other resubmissions, refer to: ‘Guidance to submitting companies for completion of New Product Assessment Form (NPAF)’.

|  |
| --- |
| * + - 1. **Registration details:**

Approved name of medicinal product:Brand name:Licensed indication:Pharmaceutical company: |
| * + - 1. **Proforma submitted by**:

Name:Position:Signature:Date: |
| * + - 1. **Checklist for completion of the proforma**

Before submitting the proforma please ensure the following checklist is complete.[ ]  The proforma is complete.[ ]  New or improved concise PAS application or confirmation of list price reduction is enclosed.**[ ]** A summary table showing updated cost effectiveness results using the new / improved PAS price or list price reduction (see section 2.2 of the guidance to submitting companies). [ ]  An appendix (or appendices) showing updated cost-effectiveness results using the new/ improved PAS price or list price reduction (see section 2.2 of the guidance to submitting companies). [ ]  A revised budget impact template for the new / improved PAS scenario or list price reduction.[ ]  A Word document showing the summary table from the budget impact template for the new/improved PAS scenario or list price reduction. |
| * + - 1. **Details of the original New Product Assessment Form (NPAF) and SMC advice**

Date SMC advice published:SMC ID No: |
| * + - 1. **Provide the justification for requesting consideration of a resubmission via the fast-track route.**
 |
| [ ]  The simple PAS has been improved and there is no other change to the submission[ ]  A new simple PAS has been submitted and there is no other change to the submission[ ]  A Department of Health confirmed list price reduction and there is no other change to the submission |
| * + - 1. **Tick to confirm that all of the following apply to the resubmission.**

[ ]  The resubmission is provided within three months of the date the original SMC decision was issued to the company. |
| [ ]  Any changes to the list price of the medicine under review are reflected in the revised documents submitted.[ ]  Any changes to the list price of comparator medicines are reflected in the revised documents submitted.[ ]  There is no change to the proposed positioning of the medicine under review.[ ]  There is no change to any other aspect of the original submission.[ ]  There has been no previous fast-track resubmission for the medicine under review. |